This Article Full Text Full Text (PDF) All Versions of this Article: 111/14/1822    most recent 01.CIR.0000160854.75779.E8v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eitzman, D. T. Articles by Ginsburg, D. Search for Related Content PubMed PubMed Citation Articles by Eitzman, D. T. Articles by Ginsburg, D. Related Collections Animal models of human disease Pathophysiology Genetically altered mice Arterial thrombosis Coagulation Thrombin Other Vascular biology Related Articles

(Circulation. 2005;111:1822-1825.)
© 2005 American Heart Association, Inc.

Vascular Medicine

Homozygosity for Factor V Leiden Leads to Enhanced Thrombosis and Atherosclerosis in Mice

Daniel T. Eitzman, MD; Randal J. Westrick, BSc; Yuechun Shen, MD; Peter F. Bodary, PhD; Shufang Gu, PhD; Sara L. Manning, BSc; Sarah L. Dobies, BSc; David Ginsburg, MD

From the Divisions of Cardiology (D.T.E., Y.S., P.F.B., S.G.) and Molecular Medicine and Genetics (D.G.); the Department of Internal Medicine, Department of Human Genetics (R.J.W., D.G.); the Life Sciences Institute (S.L.D., D.G.); and the Howard Hughes Medical Institute (S.L.M., D.G.), University of Michigan Medical Center, Ann Arbor.

Reprint requests to Daniel T. Eitzman, MD, University of Michigan Medical Center, MSRB III, Room 7301, 1150 Medical Center Dr, Ann Arbor, MI 48109-0644. E-mail deitzman{at}umich.edu

Received October 20, 2004; revision received December 22, 2004; accepted January 10, 2005.

Background— Activated protein C resistance due to factor V Leiden (FVL) is a common genetic risk factor for venous thrombosis in humans. Although the impact of FVL on the development of venous thrombosis is well established, its effect on arterial thrombosis and atherosclerosis is controversial.

Methods and Results— To determine the effect of the FVL mutation on arterial thrombosis in the mouse, wild-type (Fv^+/+), heterozygous FVL (Fv^Q/+), and homozygous FVL (Fv^Q/Q) mice underwent photochemical carotid arterial injury to induce occlusive thrombosis. Fv^Q/Q mice formed occlusive thromboses 27±3 minutes (n=7) after the onset of injury, which was significantly shorter than that observed for Fv^+/+ mice (56±7 minutes, n=9, P<0.01), whereas Fv^Q/+ mice (41±7 minutes, n=5) were intermediate (P=0.5, compared with Fv^+/+). To determine the source of FVL relevant to the enhanced vascular thrombosis, bone marrow transplantation experiments were performed between Fv^+/+ and Fv^Q/Q mice. Fv^Q/Q mice transplanted with Fv^+/+ bone marrow formed occlusive thromboses at 35±5 minutes (n=7, P<0.05 compared with Fv^+/+ mice), whereas Fv^+/+ mice transplanted with Fv^Q/Q bone marrow occluded at 59±7 minutes (n=6, P<0.001 compared with Fv^Q/Q mice). To assess the effect of the FVL mutation on the development of atherosclerosis, Fv^Q/Q mice were crossed with the atherosclerosis-prone apolipoprotein E (ApoE)–deficient strain (ApoE^–/–) to generate Fv^Q/Q,ApoE^–/– mice. By 52 weeks of age, Fv^Q/Q,ApoE^–/– mice (n=8) had developed more aortic atherosclerosis (40±6% lesion area) compared with Fv^+/+,ApoE^–/– mice (15±3% lesion area; n=12, P<0.02).

Conclusions— In conclusion, homozygosity for the FVL mutation in mice leads to enhanced arterial thrombosis and atherosclerosis. The source of the FVL leading to accelerated thrombosis appears to be circulating, non–platelet-derived plasma FVL.

Key Words: atherosclerosis • coagulation • fibrinogen • thrombosis

Related Articles:

Issue Highlights
Circulation 2005 111: 1729. [Full Text]

Another Lesson From the Factor V Leiden Mouse: Thrombin Generation Drives Arterial Disease

Steven R. Lentz
Circulation 2005 111: 1733-1734. [Full Text]

This article has been cited by other articles:

				E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]

				R. J. Westrick, M. E. Winn, and D. T. Eitzman Murine Models of Vascular Thrombosis Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2079 - 2093. [Abstract] [Full Text] [PDF]

				K. K. Koh and B.-K. Yoon Controversies regarding hormone therapy: Insights from inflammation and hemostasis Cardiovasc Res, April 1, 2006; 70(1): 22 - 30. [Abstract] [Full Text] [PDF]

				S. R. Lentz Another Lesson From the Factor V Leiden Mouse: Thrombin Generation Drives Arterial Disease Circulation, April 12, 2005; 111(14): 1733 - 1734. [Full Text] [PDF]